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Multifunctional organic nanoparticles with
aggregation-induced emission (AIE) characteristics
for targeted photodynamic therapy and RNA
interference therapy†
Guorui Jin,‡a Guangxue Feng,b Wei Qin,c Ben Zhong Tang,cd Bin Liu*ab and
Kai Li§*a
We report the design of AIE fluorogen (AIEgen)-basedmultifunctional
organic nanoparticles with surface siRNA decoration for targeted
photodynamic therapy and RNA interference therapy.
Nanoparticle-based theranostic platforms that allow the incorpora-
tion of both imaging and therapeutic reagents into one single
probe are strongly desired for cancer diagnosis and treatment,
which facilitate concurrent image-guided diagnosis and therapies.1
Among the various theranostic platforms, photodynamic therapy
(PDT) has been increasingly recognized as an attractive approach
for cancer treatment because the PDT treatment regulated by a
beam of light has distinct advantages such as precise controllabi-
lity, minimal invasive nature and high spatiotemporal accuracy.2
The mechanism of PDT is that the photosensitizers are able to
generate toxic reactive oxygen species (ROS) after light irradiation to
kill tumor cells. Additionally, the fluorescence from photosensiti-
zers could also facilitate the imaging-guided theranostic process.
However, traditional fluorescent photosensitizers generally suﬀer
from p–p stacking due to the intrinsic hydrophobic and rigid
planar molecular structures, further leading to aggregation caused
quenching (ACQ) and significant decrease in ROS generation.3
Recently, we have demonstrated that a class of fluorogens with
aggregation-induced emission (AIEgens) characteristics could act as
effective fluorescent materials for theranostic applications.4 The
propeller-shaped AIEgens are generally non-emissive in solution
but become highly emissive upon aggregation caused by the
restriction of intramolecular rotations, which block the non-
radiative pathway and activate the radiative channels for energy
dissipation.5 As such, the AIEgen-based photosensitizers are excel-
lent key components for PDT with the expectation to yield bright
emission and high phototoxicity upon loading into nanocarriers.6
This is in contrast to the traditional ACQ photosensitizers, which
offer quenched fluorescence and reduced phototoxicity in the
nanoparticle (NP) format.7
Another challenge in PDT is that the cancer cells could respond
to ROS stress by upregulating the level of vascular endothelial
growth factor (VEGF) to suppress cellular senescence by inducing
angiogenesis.8 As a result, the resistance process in tumors treated
with PDT will attenuate its therapeutic eﬀect. To address this issue,
the small interfering RNA-vascular endothelial growth factor
(siVEGF) that has been widely used to suppress VEGF expression
for inhibition of tumor growth and metastasis in cancer treat-
ments has been used to provide a promising solution.9 However,
the delivery of short small interfering RNA (siRNA) remains a key
challenge in the development of RNA interference (RNAi) thera-
peutics because of the poor stability of siRNA in a biological
environment.10 Recently, it was found that the stability of siRNA
against enzymatic degradation could be improved when siRNA
conjugated poly(ethylene glycol)-lipid forms a nanocarrier.11
Considering the above mentioned facts, a new multifunctional
theranostic platform based on AIE photosensitizers with the
ability for siRNA delivery will oﬀer a synergistic eﬀect to achieve
improved therapeutic outcome in an image-guided PDT.
In this contribution, we report multifunctional organic NPs
using an AIEgen, 2-(2,6-bis((E)-4-(phenyl(40-(1,2,2-triphenylvinyl)-
[1,10-biphenyl]-4-yl)amino)styryl)-4H-pyran-4-ylidene)malononitrile
(TTD), as the photosensitizer with the biocompatible poly(ethylene
glycol)-lipid as the encapsulation matrix. The surface of NPs was
decorated with the cyclic arginine-glycine-aspartic acid (cRGD)
peptide and siVEGF, which equipped the NPs with the ability to
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target integrin-overexpressed cells and deliver siRNA. By intro-
ducing the glutathione (GSH) cleavable disulfide bond between
DSPE-PEG and siVEGF, the elevated GSH level in cell cytoplasm
could release siVEGF from the NP surface. As a result, the
internalized NPs could trigger a synergistic eﬀect with combi-
nation of PDT and siRNA therapy to improve the overall killing
eﬃciency towards MDA-MB-231 cells (Scheme 1). As compared
to existing systems,12 our ‘‘all-in-one’’ anti-cancer platform based
on the AIE photosensitizer contains functionalities required for
image, therapy, and RNA interference.13
The fluorescent photosensitizer TTD was synthesized according
to our previous report.14 DSPE-PEG-siVEGF was synthesized
through the conjugation of DSPE-PEG-NH2 with thiol-modified
siVEGF using succinimidyl 3-(2-pyridyldithio)propionate (SPDP)
as a linker.15 Reverse-phase high performance liquid chromato-
graphy (HPLC) was applied to verify the success of conjugation.
The HPLC peaks for DSPE-PEG-NH2, DSPE-PEG-siVEGF and
siVEGF are observed at 6.985, 7.625 and 7.960 min retention
time, respectively (Fig. S1, ESI†). The shift of the retention time
of siVEGF from 7.960 min to 7.625 min indicates the successful
conjugation of siVEGF with DSPE-PEG-NH2. The siVEGF-TTD
NPs were then prepared by nanoprecipitation using a mixture of
DSPE-PEG-siVEGF and DSPE-PEG-maleimide as the encapsula-
tion matrix. The maleimide-decorated NPs were further immo-
bilized with cRGD-SH, which facilitates the targeting ability to
cancer cells with a high expression level of avb3 integrin. The
obtained cRGD-siVEGF-TTD NPs are spherical in shape under
TEM (Fig. 1A) with an eﬀective average hydrodynamic diameter
of 127  30 nm determined by dynamic light scattering. The
optical properties of cRGD-siVEGF-TTD NPs were also studied,
which showed intense absorption peaks at 350 and 494 nm with
an emission maximum at 682 nm in water (Fig. 1B). It has been
reported that the TTD molecules showed typical twisted intra-
molecular charge transfer and AIE characteristics (Fig. S2,
ESI†),14 which yielded cRGD-siVEGF-TTD NPs with a quantum
yield of (12%  1%) in water (inset in Fig. 1B), measured using
Rhodamine 6G in methanol as the standard.
Typically, intersystem crossing occurs from the singlet excited
state to the triplet state upon excitation of the photosensitizers,
which is followed by reaction withmolecular oxygen to yield ROS,
including singlet oxygen (1O2).
16 To achieve satisfied therapeutic
outcome, photosensitizers with a high 1O2 yield is desirable.
17
Therefore, the 1O2 quantum yield of cRGD-siVEGF-TTD NPs
(FTTD) was quantified using 9,10-anthracenediyl-bis(methylene)-
dimalonic acid (ABDA) as the indicator and Rose Bengal (RB) as the
standard photosensitizer (the 1O2 quantum yield for FRB is 75% in
water).18 In the presence of 1O2, ABDA could undergo oxidation to
yield endoperoxide, resulting in a decrease of ABDA absorption.19
Under white light irradiation, the absorbance of ABDA solution
with cRGD-siVEGF-TTD NPs decreased gradually with prolonged
irradiation time (Fig. S3, ESI†), indicating the generation of 1O2
from cRGD-siVEGF-TTD NPs in the solution. The absorbance of
ABDA in the presence of the photosensitizer (cRGD-siVEGF-TTD
NPs or RB) at 378 nm before and after irradiation was defined as A0
and A, respectively. The plot of ln(A0/A) against time gives straight
lines in Fig. 1C. From the slopes, the decomposition rate constants
(KTTD) of cRGD-siVEGF-TTD NPs and RB (KRB) could be calculated
as 0.0058 and 0.0072, respectively. The integrations of the optical
absorption in the wavelength range of 400–800 nm for RB (ARB) and
cRGD-siVEGF-TTD NPs (ATTD) were 21.09 and 18.68, respectively.
The 1O2 quantum yield of cRGD-siVEGF-TTD NPs was calculated to
be 68.2%. The in vitro release profiles of siVEGF from cRGD-
siVEGF-TTD NPs were also studied in 1 PBS buffer with or
without GSH. The concentration of GSH solution is 10 mM,
mimicking intracellular reductive conditions.20 It is known that
the concentration of GSH in intracellular compartments is signifi-
cantly higher than that in extracellular plasma and the difference
in GSH concentration between cytoplasm and extracellular space
provides a great potential in achieving highly efficient delivery and
controlled release of siVEGF that was conjugated on the surface of
Scheme 1 Illustration of conjugation of DSPE-PEG-NH2 with siVEGF and
formation of the TTD loaded and cRGD conjugated siVEGF-TTD nano-
particles (cRGD-siVEGF-TTDNPs). Succinimidyl 3-(2-pyridyldithio)propionate
(SPDP) is the linker applied for conjugation of siVEGF with DSPE-PEG-NH2.
Fig. 1 (A) Transmission electronmicroscopy (TEM) image of cRGD-siVEGF-
TTD NPs. The scale bar is 200 nm. (B) UV-vis absorption and emission
(lex = 494 nm) spectra of cRGD-siVEGF-TTD NPs in water. The inset shows a
photo of NPs in water under UV lamp. (C) The decomposition rates of ABDA in
the presence of cRGD-siVEGF-TTD NPs and RB; A0 and A are the absorbance
of ABDA in the presence of the photosensitizers at 378 nm before and after
irradiation, respectively. (D) Time course of release profiles of siVEGF from
cRGD-siVEGF-TTD NPs in 1 PBS buﬀer with or without GSH at 37 1C.
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cRGD-siVEGF-TTD NPs through disulfide bonds.21 As shown in
Fig. 1D, faster release of siVEGF was triggered in the presence of
GSH, suggesting that 31% and 73% of the siVEGF were released in
the GSH-supplemented buffer after 6 and 72 h, respectively.
However, only 18% and 47% of the siVEGF were released in
buffer without GSH after 6 and 72 h, respectively. These data
revealed that the effective intracellular release of siVEGF could
be expected in cell cytoplasm upon internalization.
The targeting eﬀect of cRGD-siVEGF-TTD NPs was investigated
using MDA-MB-231 cancer cells with overexpressed avb3 integrin
as the target cells, while MCF-7 and SK-BR-3 cancer cells with
low expression level of avb3 integrin were used as the negative
controls.22 The fluorescence signals of NPs in MDA-MB-231,
MCF-7 and SK-BR-3 cells were recorded under a confocal micro-
scope after incubation with cRGD-siVEGF-TTDNPs at 5 mgmL1 of
TTD for 4 h. As shown in Fig. 2, strong red fluorescence from the
internalized NPs in the cytoplasm was clearly observed in MDA-
MB-231 cells (Fig. 2A). In contrast, the MCF-7 and SK-BR-3 cells
showed much weaker fluorescence, indicating the higher inter-
nalization eﬃciency of cRGD-functionalized NPs in MDA-MB-231
cells. This observation was consistent with the mean fluorescence
intensity of each cell quantitatively analyzed by ImageJ from
confocal images of MDA-MB-231, MCF-7, and SK-BR-3 cells (Fig.
S4, ESI†). To evaluate the ROS productivity by cRGD-siVEGF-TTD
NPs after cancer cell uptake, a cell permeable fluorescent reagent
(CellROXs deep red reagent) was employed to detect the ROS
generation under light irradiation. In the presence of ROS, the
CellROXs deep red reagent could be rapidly oxidized to exhibit
a strong red fluorescence. As shown in Fig. 2B, a strong red
fluorescence was observed from the cell cytoplasm, suggesting
eﬃcient ROS generation from the cRGD-siVEGF-TTD NPs. The
NP-treated cells without light irradiation were used as control. No
fluorescence could be observed from the cells under a confocal
microscope with the same parameters (Fig. S5, ESI†), further
confirming that the red fluorescence is only from the oxidized
CellROXs deep red reagent in the presence of ROS.
Several research groups have reported that the overexpression of
angiogenic factors (such as VEGF) in tumor cells after PDT could
lead to the cell resistance to PDT.23 To eliminate such resistance
induced by angiogenesis following PDT, cRGD-siVEGF-TTDNPswith
surface siVEGF conjugation were delivered to the targeted cancer
cells, and confocal laser scanning microscopy (CLSM) was employed
to visualize the cellular delivery of siVEGF. As cRGD-siVEGF-TTDNPs
are red emissive, Cy3 modified siVEGF and cRGD were incorporated
into a green AIEgen of 4,7-bis[4-(1,2,2-triphenylvinyl)phenyl]benzo-
2,1,3-thiadiazole (BTPETD) based NPs fabricated using the same
method as that used for red cRGD-siVEGF-TTD NPs. The obtained
cRGD-Cy3-siVEGF-BTPETD NPs have an average size of B130 nm,
and the green fluorescence could be eﬀectively diﬀerentiated from
the red signal for Cy3 conjugated siVEGF during confocal imaging
(Fig. S6, ESI†). After incubation with MDA-MB-231 cells for 4 h, both
green and red signals from BTPETD and Cy3 were detected from the
cytoplasm with good coherence (Fig. S7, ESI†), suggesting that the
siVEGF could be successfully delivered into target cells. The eﬀect of
siVEGF delivery on VEGF expression in target cells was further
quantitatively evaluated through investigation of the relative VEGF
protein andmRNA levels in MDA-MB-231 cells after incubation with
cRGD-siVEGF-TTD NPs. After incubating the cells with cRGD-
siVEGF-TTD NPs for 4 h, followed by culturing in fresh medium
for another 48 h, VEGF protein in culture medium and VEGFmRNA
in cell lysate were then individually analyzed using the VEGF
Quantikine ELISA Kit and reverse transcription polymerase chain
reaction (RT-PCR), respectively. As shown in Fig. 3A, cRGD-siVEGF-
TTDNPs could eﬀectively downregulate the VEGF protein expression
level by 50% and the VEGF mRNA expression level by 64% as
compared to the cells without NP treatment. As a result, the
delivered siVEGF could significantly reduce VEGF expression,
leading to attenuated resistance to PDT in cancer cells.24
To evaluate the cytotoxicity of TTD, cRGD-TTD NPs without
siVEGF were fabricated from the same nanoprecipitation method
using DSPE-PEG-Mal as the encapsulation matrix. MTT results
indicated that the viability of MDA-MB-231 cells was kept at above
90% after incubation with cRGD-TTDNPs at 10, 20 and 30 mgmL1
of TTD for 48 h, indicating the low cytotoxicity of cRGD-TTD NPs to
cells (Fig. S8, ESI†). The synergistic eﬀect of PDT and RNAi
therapy from cRGD-siRNA-TTD NPs was further evaluated by
Fig. 2 (A) Confocal images of MDA-MB-231, MCF-7, and SK-BR-3 cells after
incubation with cRGD-siVEGF-TTD NPs (5 mg mL1 of TTD) for 4 h at 37 1C.
The red fluorescence signal was from cRGD-siVEGF-TTD NPs (lex = 488 nm
with a 560 nm above longpass filter). (B) Detection of intracellular ROS
generation in living MDA-MB-231 cells after incubation with cRGD-siVEGF-
TTD NPs (5 mg mL1 of TTD) and CellROXs deep red reagent, followed by
light irradiation (lex = 633 nm; 650 nm above longpass filter).
Fig. 3 (A) The relative VEGF protein level in culture medium of cRGD-
siVEGF-TTD NPs (5 mg mL1 of TTD) treated MDA-MB-231 cells and the
VEGF mRNA level determined from the lysate of MDA-MB-231 cells.
Controls were shown in black and set to be 100%. (B) Viability of MDA-
MB-231, MCF-7 and SK-BR-3 cells after incubation with cRGD-siVEGF-TTD
NPs (5 mg mL1 of TTD) for 4 h followed by light irradiation (0.20 W cm2,
10 min) and further incubation in fresh medium for 24 and 48 h. Data
present mean values  standard deviation, n = 3.
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the MTT assay. SK-BR-3, MCF-7 and MDA-MB-231 cells were
incubated with cRGD-siRNA-TTD NPs at 5 mg mL1 of TTD for
4 h. The free NPs were washed away and the cells were exposed
to 0.2 W cm2 light irradiation for 10 minutes, followed by
incubation in fresh medium for 24 and 48 h, respectively. The
results suggested that the cRGD-siVEGF-TTD NPs showed
obvious cytotoxicity to MDA-MB-231 cells and the viability of
MDA-MB-231 cells without light illumination decreased to 61%
after 48 h, which was mainly caused by delivered siVEGF
though RNA interference. Exposure to light irradiation resulted
in a further decrease of the viability of MDA-MB-231 cells to
25% after 48 h. It is noteworthy that the viability of MDA-MB-
231 cells treated with cRGD-TTD NPs without surface siVEGF
remained 70% after the same PDT treatment while the light
irradiation itself did not cause damage to cell viability (Fig. S9,
ESI†). These data confirmed the synergistic eﬀect of RNA
interference and PDT eﬀect, which could lead to more eﬀective
therapeutic outcome. From Fig. 3B, it could also be seen that
the viability of MDA-MB-231 cells after cRGD-siVEGF-TTD NP
treatment was significantly lower as compared to that of SK-BR-3
and MFC-7 cells under the same experimental conditions, reveal-
ing the targeted therapeutic eﬀect of cRGD-siVEGF-TTD NP to
integrin-overexpressed cancer cells.
In conclusion, a new multifunctional AIE NP based siRNA
vector was successfully developed for combined image-guided
PDT and RNAi therapy for targeted cancer cells. The platform
shows bright fluorescence and could eﬀectively generate ROS
under light irradiation. VEGF siRNA conjugated on the surface
of NPs has been successfully transfected to cancer cells to
downregulate VEGF mRNA and protein expressions. Cell viability
studies showed that the siVEGF-TTD NPs could selectively and
eﬃciently kill the avb3 integrin overexpressed cancer cells with
the synergistic eﬀect between PDT and RNA interference. In
future, AIE photosensitizers with eﬃcient absorption in the long
wavelength region will be promising for exploring the potential of
such a multifunctional theranostic platform in in vivo research.
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